Ocular Itch Relief with Alcaftadine 0.25% Versus Olopatadine 0.2% in Allergic Conjunctivitis: Pooled Analysis of Two Multicenter Randomized Clinical Trials

Antzeko izenburuak

• Effect of alcaftadine 0.25% on ocular itch associated with seasonal or perennial allergic conjunctivitis: a pooled analysis of two multicenter randomized clinical trials
  nork: Ciolino, Joseph B, et al.
  Argitaratua: (2015)
• A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model
  nork: Ackerman, Stacey, et al.
  Argitaratua: (2013)
• Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis
  nork: Ayyappanavar, Shruti, et al.
  Argitaratua: (2021)
• Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis
  nork: Lakshey Dudeja, et al.
  Argitaratua: (2019-01-01)
• Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis
  nork: Dudeja, Lakshey, et al.
  Argitaratua: (2019)